title: Targeting angiogenesis in head and neck cancer.
abstract: Angiogenesis is a crucial step in tumor growth and metastasis. Head and neck squamous cell carcinomas (HNSCC) highly express angiogenesis factors, such as vascular endothelial growth factor (VEGF), which are associated with patient prognosis. Antiangiogenesis agents can potentially modulate tumor microenvironment and induce radiosensitivity and chemosensitivity. In this review, we discuss the molecular mechanisms underlying angiogenesis involved in HNSCC, preclinical data with antiangiogenesis agents as well as potential predictive biomarkers. We also review novel therapies under investigation and summarize the results of clinical trials using antiangiogenesis agents alone or in combination with conventional therapies in HNSCC.
authors: Royal Marsden Hospital, London, UK.
authors: Maria
authors: M
authors: Vassilakopoulou
authors: Attikon Hospital and Medical School of Athens, Athens, Greece.
authors: Amanda
authors: A
authors: Psyrri
authors: Hygeia Hospital, Athens, Greece; University of Texas Health Science Center at San Antonio, TX, USA. Electronic address: athanassios.argiris@gmail.com.
authors: Athanassios
authors: A
authors: Argiris
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D006258:Head and Neck Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D006801:Humans; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000628:therapy*; D011379:Prognosis
keywords: Angiogenesis; Bevacizumab; Head and neck cancer; Monoclonal antibodies; Targeted therapy; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Vascular endothelial growth factor receptor